美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Eikon Therapeutics

11.39

+0.64005.95%

盘后：11.390.00000.00%19:51 EDT

成交量：53.28万

成交额：619.20万

市值：6.15亿

市盈率：-1.91

高：12.11

开：10.87

低：10.75

收：10.75

52周最高：17.40

52周最低：7.90

股本：5,398.43万

流通股本：1,764.80万

量比：0.71

换手率：3.02%

股息：- -

股息率：- -

每股收益(TTM):-5.9500

每股收益(LYR):-115.2900

净资产收益率：-125.02%

总资产收益率：-36.19%

市净率：1.32

市盈率(LYR):-0.10

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

营收暴增无阻英派药业继续亏损：预计上半年减亏三成左右！股价早已破发

深圳商报·读创

Eikon Therapeutics宣布晚期黑色素瘤Eik1001适应症2/3期试验Teluride-006进入剂量选择阶段

Eikon Therapeutics宣布Teluride-008临床试验首位患者给药，Eik1001用于非小细胞肺癌的注册性II/III期研究正式启动

新闻稿：Eikon Therapeutics 宣布任命 Ma. Fatima D. Francisco 加入董事会

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/EIKN"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EIKN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EIKN\",,,,,undefined,":{"symbol":"EIKN","market":"US","secType":"STK","nameCN":"Eikon Therapeutics","latestPrice":11.39,"timestamp":1787342400000,"preClose":10.75,"halted":0,"volume":532797,"hourTrading":{"tag":"盘后","latestPrice":11.39,"preClose":11.39,"latestTime":"19:51 EDT","volume":1595,"amount":18156.859,"timestamp":1787356271240,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.059534883720930284,"floatShares":17648000,"shares":53984300,"eps":-5.95,"marketStatus":"未开盘","change":0.64,"latestTime":"08-21 16:00:00 EDT","open":10.87,"high":12.11,"low":10.75,"amount":6192018.616434,"amplitude":0.126512,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-5.95,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":0,"adr":0,"listingDate":1770267600000,"exchange":"NASDAQ","adjPreClose":10.75,"preHourTrading":{"tag":"盘前","latestPrice":10.84,"preClose":10.75,"latestTime":"09:28 EDT","volume":4639,"amount":50889.704746999996,"timestamp":1787318880048,"change":0.09,"changeRate":0.008372,"amplitude":0.012093},"postHourTrading":{"tag":"盘后","latestPrice":11.39,"preClose":11.39,"latestTime":"19:51 EDT","volume":1595,"amount":18156.859,"timestamp":1787356271240,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7071557181929533},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EIKN\",,,,,undefined,":{"symbol":"EIKN","floatShares":17648000,"roa":"-36.19%","roe":"-125.02%","lyrEps":-115.29,"volumeRatio":0.7071557181929533,"shares":53984300,"dividePrice":0,"high":12.11,"amplitude":0.126512,"preClose":10.75,"low":10.75,"week52Low":7.9,"pbRate":"1.32","week52High":17.4,"institutionHeld":0,"latestPrice":11.39,"eps":-5.95,"divideRate":0,"volume":532797,"delay":0,"ttmEps":-5.95,"open":10.87,"prevYearClose":18,"prevWeekClose":11.05,"prevMonthClose":9.21,"prevQuarterClose":13.05,"fiveDayClose":11.05,"twentyDayClose":8.9,"sixtyDayClose":10.37},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EIKN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"EIKN","fiscalQuarterEnding":"2026/06","expectedEps":-1.61,"name":null,"time":"盘后","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-1.63},{"market":"US","date":"2026-05-11","symbol":"EIKN","fiscalQuarterEnding":"2026/03","expectedEps":-1.47,"name":null,"time":"盘后","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-2.46}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EIKN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EIKN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.6667,"hold":0,"sell":0,"strongSell":0.1667,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1774929600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EIKN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EIKN","date":"2026-08-21","current":-1.914286,"percent":0.422222,"low":-3.139466,"twenty":-2.105086,"median":-1.719889,"eighty":-1.534894,"high":-1.335246,"avg":-1.859189,"sd":0.392485,"marketCap":582274072},"quantilePoints":[{"date":"2026-02-06","current":-2.616222,"twenty":-3.034817,"median":-2.877844,"eighty":-2.720871,"marketCap":809765055},{"date":"2026-02-13","current":-2.586571,"twenty":-2.610292,"median":-2.537735,"eighty":-2.527619,"marketCap":800587717},{"date":"2026-02-20","current":-2.703429,"twenty":-2.7418,"median":-2.616222,"eighty":-2.529014,"marketCap":836757223},{"date":"2026-02-27","current":-2.379017,"twenty":-2.703429,"median":-2.596164,"eighty":-2.52727,"marketCap":736346356},{"date":"2026-03-06","current":-2.535991,"twenty":-2.644128,"median":-2.595292,"eighty":-2.523782,"marketCap":784932259},{"date":"2026-03-13","current":-2.054606,"twenty":-2.624942,"median":-2.562153,"eighty":-2.406924,"marketCap":635935489},{"date":"2026-03-20","current":-1.915074,"twenty":-2.616222,"median":-2.529014,"eighty":-2.298787,"marketCap":592748020},{"date":"2026-03-27","current":-1.836588,"twenty":-2.600524,"median":-2.515933,"eighty":-2.054606,"marketCap":568455068},{"date":"2026-04-02","current":-1.678228,"twenty":-2.599129,"median":-2.426109,"eighty":-1.985189,"marketCap":544162116},{"date":"2026-04-10","current":-1.504368,"twenty":-2.597385,"median":-2.379017,"eighty":-1.821565,"marketCap":487788380},{"date":"2026-04-17","current":-1.876704,"twenty":-2.595641,"median":-2.269137,"eighty":-1.751381,"marketCap":608517358},{"date":"2026-04-24","current":-1.786542,"twenty":-2.595292,"median":-2.061583,"eighty":-1.769507,"marketCap":579282538},{"date":"2026-05-01","current":-1.605383,"twenty":-2.588315,"median":-2.045013,"eighty":-1.651966,"marketCap":520542206},{"date":"2026-05-08","current":-1.531083,"twenty":-2.547502,"median":-1.986901,"eighty":-1.641614,"marketCap":496450549},{"date":"2026-05-15","current":-2.105086,"twenty":-2.53634,"median":-1.963159,"eighty":-1.651966,"marketCap":713546154},{"date":"2026-05-22","current":-1.782455,"twenty":-2.530409,"median":-1.936811,"eighty":-1.659647,"marketCap":604186273},{"date":"2026-05-29","current":-1.645097,"twenty":-2.527968,"median":-1.929027,"eighty":-1.650964,"marketCap":557627116},{"date":"2026-06-05","current":-1.562046,"twenty":-2.525177,"median":-1.895889,"eighty":-1.633553,"marketCap":529475781},{"date":"2026-06-12","current":-1.360801,"twenty":-2.514363,"median":-1.841551,"eighty":-1.597703,"marketCap":461261110},{"date":"2026-06-18","current":-1.55406,"twenty":-2.482968,"median":-1.809917,"eighty":-1.567693,"marketCap":526768850},{"date":"2026-06-26","current":-1.573226,"twenty":-2.429947,"median":-1.776985,"eighty":-1.53713,"marketCap":533265485},{"date":"2026-07-02","current":-1.95655,"twenty":-2.406226,"median":-1.79823,"eighty":-1.541282,"marketCap":663198193},{"date":"2026-07-10","current":-1.79204,"twenty":-2.398552,"median":-1.809917,"eighty":-1.555657,"marketCap":607435406},{"date":"2026-07-17","current":-1.589198,"twenty":-2.377273,"median":-1.784498,"eighty":-1.563963,"marketCap":538679348},{"date":"2026-07-24","current":-1.536491,"twenty":-2.355995,"median":-1.761474,"eighty":-1.543838,"marketCap":520813601},{"date":"2026-07-31","current":-1.536491,"twenty":-2.298787,"median":-1.731347,"eighty":-1.536491,"marketCap":520813601},{"date":"2026-08-07","current":-1.471006,"twenty":-2.239486,"median":-1.715581,"eighty":-1.534894,"marketCap":498616763},{"date":"2026-08-14","current":-1.736786,"twenty":-2.116266,"median":-1.712181,"eighty":-1.534894,"marketCap":559524759},{"date":"2026-08-21","current":-1.807401,"twenty":-2.105086,"median":-1.719889,"eighty":-1.534894,"marketCap":582274072}],"updateTime":1787526641762},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EIKN\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658911994","title":"营收暴增无阻英派药业继续亏损：预计上半年减亏三成左右！股价早已破发","url":"https://stock-news.laohu8.com/highlight/detail?id=2658911994","media":"深圳商报·读创","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658911994?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 23:03","pubTimestamp":1786460583,"startTime":"0","endTime":"0","summary":"8月11日，英派药业(07630.HK)发布盈利预告，公司预计2026年上半年收入约9470万元至1.16亿元，较去年同期约2520万元增长约276%至359%；预计期内亏损约8170万元至9990万元，较去年同期约1.29亿元减少约22%至37%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113838249182.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113838249182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","BK1161","EIKN","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143932807","title":"Eikon Therapeutics宣布晚期黑色素瘤Eik1001适应症2/3期试验Teluride-006进入剂量选择阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1143932807","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143932807?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 19:31","pubTimestamp":1786447878,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics今日对外披露，其针对晚期黑色素瘤开展的在研药物Eik1001，已正式进入一项名为Teluride-006的适应性2/3期临床试验的剂量选择阶段。这一里程碑标志着该研究方案向前迈出了关键一步。Eikon Therapeutics专注于开发创新疗法，以攻克难治性癌症。此次剂量选择的宣布，体现了公司对于严谨临床试验流程的坚守，以及对加速推进Eik1001临床开发进度的决心。市场分析人士正密切关注这一进展，因为若试验结果积极，Eik1001有望为晚期黑色素瘤患者群体带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181280733","title":"Eikon Therapeutics宣布Teluride-008临床试验首位患者给药，Eik1001用于非小细胞肺癌的注册性II/III期研究正式启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1181280733","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181280733?lang=zh_cn&edition=fundamental","pubTime":"2026-07-27 19:32","pubTimestamp":1785151940,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics今日宣布，其在研药物Eik1001的注册性II/III期临床试验——Teluride-008，已完成首位患者给药。这项研究专注于非小细胞肺癌（NSCLC）的治疗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116184350","title":"新闻稿：Eikon Therapeutics 宣布任命 Ma. Fatima D. Francisco 加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1116184350","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116184350?lang=zh_cn&edition=fundamental","pubTime":"2026-06-08 20:04","pubTimestamp":1780920252,"startTime":"0","endTime":"0","summary":"加州米尔布雷，2026年6月8日——致力于开发创新药物以解决严重未满足医疗需求的后期临床生物制药公司 Eikon Therapeutics, Inc.  今日宣布，任命 Ma. FatimaD. Francisco 女士为公司董事会独立董事，自2026年6月15日起生效。Francisco 女士还将担任董事会薪酬委员会成员。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/EIKN\",params:#limit:6,delay:false,,,undefined,":[]}}